Format
Sort by
Items per page

Send to

Choose Destination

Links from Books

Items: 1 to 20 of 36

1.

Relaxin increases human endothelial progenitor cell NO and migration and vasculogenesis in mice.

Segal MS, Sautina L, Li S, Diao Y, Agoulnik AI, Kielczewski J, McGuane JT, Grant MB, Conrad KP.

Blood. 2012 Jan 12;119(2):629-36. doi: 10.1182/blood-2011-04-346007. Epub 2011 Oct 25.

2.

Relaxin remodels fibrotic healing following myocardial infarction.

Samuel CS, Cendrawan S, Gao XM, Ming Z, Zhao C, Kiriazis H, Xu Q, Tregear GW, Bathgate RA, Du XJ.

Lab Invest. 2011 May;91(5):675-90. doi: 10.1038/labinvest.2010.198. Epub 2011 Jan 10.

3.

Heart disease and stroke statistics--2011 update: a report from the American Heart Association.

Roger VL, Go AS, Lloyd-Jones DM, Adams RJ, Berry JD, Brown TM, Carnethon MR, Dai S, de Simone G, Ford ES, Fox CS, Fullerton HJ, Gillespie C, Greenlund KJ, Hailpern SM, Heit JA, Ho PM, Howard VJ, Kissela BM, Kittner SJ, Lackland DT, Lichtman JH, Lisabeth LD, Makuc DM, Marcus GM, Marelli A, Matchar DB, McDermott MM, Meigs JB, Moy CS, Mozaffarian D, Mussolino ME, Nichol G, Paynter NP, Rosamond WD, Sorlie PD, Stafford RS, Turan TN, Turner MB, Wong ND, Wylie-Rosett J; American Heart Association Statistics Committee and Stroke Statistics Subcommittee.

Circulation. 2011 Feb 1;123(4):e18-e209. doi: 10.1161/CIR.0b013e3182009701. Epub 2010 Dec 15. No abstract available. Erratum in: Circulation. 2011 Oct 18;124(16):e426. Circulation. 2011 Feb 15;123(6):e240.

4.

Antifibrotic properties of relaxin: in vivo mechanism of action in experimental renal tubulointerstitial fibrosis.

Hewitson TD, Ho WY, Samuel CS.

Endocrinology. 2010 Oct;151(10):4938-48. doi: 10.1210/en.2010-0286. Epub 2010 Sep 8.

PMID:
20826562
5.

Relaxin: review of biology and potential role in treating heart failure.

Teichman SL, Unemori E, Teerlink JR, Cotter G, Metra M.

Curr Heart Fail Rep. 2010 Jun;7(2):75-82. doi: 10.1007/s11897-010-0010-z. Review.

6.

Cardiovascular effects of relaxin: from basic science to clinical therapy.

Du XJ, Bathgate RA, Samuel CS, Dart AM, Summers RJ.

Nat Rev Cardiol. 2010 Jan;7(1):48-58. doi: 10.1038/nrcardio.2009.198. Epub 2009 Nov 24. Review.

PMID:
19935741
7.

Activation of relaxin-related receptors by short, linear peptides derived from a collagen-containing precursor.

Shemesh R, Hermesh C, Toporik A, Levine Z, Novik A, Wool A, Kliger Y, Rosenberg A, Bathgate RA, Cohen Y.

Ann N Y Acad Sci. 2009 Apr;1160:78-86. doi: 10.1111/j.1749-6632.2009.03827.x.

PMID:
19416163
8.

Relaxin for the treatment of patients with acute heart failure (Pre-RELAX-AHF): a multicentre, randomised, placebo-controlled, parallel-group, dose-finding phase IIb study.

Teerlink JR, Metra M, Felker GM, Ponikowski P, Voors AA, Weatherley BD, Marmor A, Katz A, Grzybowski J, Unemori E, Teichman SL, Cotter G.

Lancet. 2009 Apr 25;373(9673):1429-39. doi: 10.1016/S0140-6736(09)60622-X. Epub 2009 Mar 28.

PMID:
19329178
9.

Functional and histopathological improvement of the post-infarcted rat heart upon myoblast cell grafting and relaxin therapy.

Bonacchi M, Nistri S, Nanni C, Gelsomino S, Pini A, Cinci L, Maiani M, Zecchi-Orlandini S, Lorusso R, Fanti S, Silvertown J, Bani D.

J Cell Mol Med. 2009 Sep;13(9B):3437-48. doi: 10.1111/j.1582-4934.2008.00503.x. Epub 2008 Sep 15.

10.

Relaxin as a protective substance in preservation solutions for organ transplantation, as shown in an isolated perfused rat liver model.

Boehnert MU, Armbruster FP, Hilbig H.

Transplant Proc. 2008 May;40(4):978-80. doi: 10.1016/j.transproceed.2008.03.038.

PMID:
18555094
11.

Relaxin ameliorates fibrosis in experimental diabetic cardiomyopathy.

Samuel CS, Hewitson TD, Zhang Y, Kelly DJ.

Endocrinology. 2008 Jul;149(7):3286-93. doi: 10.1210/en.2008-0250. Epub 2008 Apr 3.

PMID:
18388190
12.

The vascular actions of relaxin.

Jeyabalan A, Shroff SG, Novak J, Conrad KP.

Adv Exp Med Biol. 2007;612:65-87. Review.

PMID:
18161482
13.

Relaxin promotes prostate cancer progression.

Feng S, Agoulnik IU, Bogatcheva NV, Kamat AA, Kwabi-Addo B, Li R, Ayala G, Ittmann MM, Agoulnik AI.

Clin Cancer Res. 2007 Mar 15;13(6):1695-702.

14.

Relaxin receptors--new drug targets for multiple disease states.

Van Der Westhuizen ET, Summers RJ, Halls ML, Bathgate RA, Sexton PM.

Curr Drug Targets. 2007 Jan;8(1):91-104. Review.

PMID:
17266534
15.

Comparison of signaling pathways activated by the relaxin family peptide receptors, RXFP1 and RXFP2, using reporter genes.

Halls ML, Bathgate RA, Summers RJ.

J Pharmacol Exp Ther. 2007 Jan;320(1):281-90. Epub 2006 Oct 25.

16.

Quantitative high-throughput screening: a titration-based approach that efficiently identifies biological activities in large chemical libraries.

Inglese J, Auld DS, Jadhav A, Johnson RL, Simeonov A, Yasgar A, Zheng W, Austin CP.

Proc Natl Acad Sci U S A. 2006 Aug 1;103(31):11473-8. Epub 2006 Jul 24.

17.

Protective effects of relaxin in ischemia/reperfusion-induced intestinal injury due to splanchnic artery occlusion.

Masini E, Cuzzocrea S, Mazzon E, MuiĆ  C, Vannacci A, Fabrizi F, Bani D.

Br J Pharmacol. 2006 Aug;148(8):1124-32. Epub 2006 Jul 17.

18.

Relaxin family peptide receptors RXFP1 and RXFP2 modulate cAMP signaling by distinct mechanisms.

Halls ML, Bathgate RA, Summers RJ.

Mol Pharmacol. 2006 Jul;70(1):214-26. Epub 2006 Mar 28.

19.

International Union of Pharmacology LVII: recommendations for the nomenclature of receptors for relaxin family peptides.

Bathgate RA, Ivell R, Sanborn BM, Sherwood OD, Summers RJ.

Pharmacol Rev. 2006 Mar;58(1):7-31. Review.

20.

The role of relaxin in endometrial cancer.

Kamat AA, Feng S, Agoulnik IU, Kheradmand F, Bogatcheva NV, Coffey D, Sood AK, Agoulnik AI.

Cancer Biol Ther. 2006 Jan;5(1):71-7. Epub 2006 Jan 31.

PMID:
16322684

Supplemental Content

Support Center